Morgans just added this ASX 100 blue-chip stock to its "conviction buy" list

The market weakness won't last and Morgans thinks this is a great opportunity to load up on quality stocks starting with those on its S&P/ASX 100 (Index:^ATOI) (ASX: XTO) conviction list.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

The ResMed (Resmed Inc (ASX:RMD)) share price is waning this morning as the sleep disorder treatment device maker tries to regain favour with the market.

ResMed's share price fell 0.9% to $14.68 in late morning trade as the S&P/ASX 200 (Index:^AXJO) (ASX: XJO) index eased 0.2%.

Its shares are down nearly 9% since October as growth stocks on high price-earnings (P/E) multiples have lost favour with investors amid rising US government bond yields and worries that these market darlings have run ahead of fundamentals.

The company has managed to recover from some of its steeper losses since it posted a credible first quarter result on October 26 but questions remain if the stock can retest its record high of $16.04 that it hit at the start of last month.

Morgans thinks it can and has just added ResMed to its "high conviction" stock list and has offered three reasons for investors to buy the stock.

"The company remains well positioned, in our view, with continued growth across masks and devices, a solid pipeline of new products and an expanding digital platform helping to drive resupply, low setup costs and improve adherence rates," said the broker.

"1Q results were above expectations, driven by the fifth straight quarter of double-digit sales growth, an expanding product range, stable GMs and strength in the company's leading connected-care offerings."

Thirdly, there's still plenty of growth left ahead for ResMed. Morgans noted that 12 million Americans suffer from sleep apnoea (based on statistics from the US National Heart Blood and Lung Institute) but ResMed said less than four million are diagnosed or treated each year – and that's only for the US.

Morgans has a $16.40 price target on the stock.

But ResMed isn't the only S&P/ASX 100 (Index:^ATOI) (ASX: XTO) stock on Morgans' conviction list. Copper miner OZ Minerals Limited (ASX: OZL), plumbing products group Reliance Worldwide Corporation Ltd (ASX: RWC) and our second largest mortgage lender Westpac Banking Corp (ASX: WBC) are also on the list.

Coincidentally, OZ Minerals share price is surging 2.3% at the time of writing to $9.47 thanks to stronger copper prices overnight and bullish market sentiment towards the mining sector.

On the flipside, Westpac's share price is struggling to keep its head above breakeven after the bank handed in its full-year profit report card, while Reliance Worldwide's share price is down 1.5% at $5.11.

Looking for other blue-chips to put on your watchlist? The experts at the Motley Fool have picked three of their best blue-chip stock ideas for FY19 and you can find out what these are for free by following the link below.

Motley Fool contributor Brendon Lau owns shares of Reliance Worldwide Limited and Westpac Banking. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cheap Shares

A group of people in suits watch as a man puts his hand up to take the opportunity.
Cheap Shares

A rare buying opportunity in 1 of Australia's top shares?

Here’s why I think it’s a strong long-term buy…

Read more »

Buy and sell keys on an Apple keyboard.
Cheap Shares

2 ASX shares highly recommended to buy: Experts

Many experts like these ASX shares. Here’s why…

Read more »

patient with doctor, medical company, medical insurance
Cheap Shares

CSL shares trade at just 12 times forecast earnings. Here's why they could be the buy of the decade

The ASX 200 healthcare giant is down more than 60% since August 2025.

Read more »

A white and black clock face is shown with Time to Buy written.
Cheap Shares

2 ASX shares tipped to grow 90% or more in the next 12 months

These businesses are expected to deliver significant returns.

Read more »

A man reacts with surprise when her see a bargain price on his phone.
Cheap Shares

This ASX 300 share is down 63% in 2026: Experts think it's a buy!

This business could be a great contrarian buy.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Cheap Shares

Down 40%+! 2 cheap ASX shares I'd buy before the recovery becomes obvious

The best recovery opportunities can appear before the good news is obvious. I think these two ASX shares are worth…

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Cheap Shares

3 cheap ASX 200 shares to buy with $5,000

Big returns could be on offer with these cheap shares according to analysts.

Read more »

Rising arrow on a piggy bank with a woman holding it and smiling.
Growth Shares

2 ASX growth shares to buy with big growth potential!

Analysts are excited about the prospects of these businesses…

Read more »